---

In a September 2023 lecture in Dornach, Switzerland, Dr. David E. Martin detailed how it is known that SARS-CoV-2 is a man-made biological weapon whose development began 58 years ago.

Dr. Martin said that the ” coronavirus ” virus was first described in 1965. Two years later, healthy British military personnel were infected with coronavirus pathogens from the US “as part of our biological weapons program.”

In 1992, Ralph Baric at the University of North Carolina, Chapel Hill, took a pathogen that used to infect the gut and lungs and altered it with a chimaera to make it infect the heart, causing cardiomyopathy.  This research was part of the effort to develop an HIV vaccine.

The covid injections were 19 years in the making by the time they were rolled out.  These injections were rolled out despite the mRNA spike protein being publicly referred to as a bio-weapon almost 20 years ago. In 2005, the mRNA spike protein was presented at a conference organised by DARPA and Miter Corporation as a “technology that enables biological warfare.”

Towards the end of his lecture, Dr. Martin summarised some of the key points in the timeline of the conspiracy to commit global genocide:

• 2002 – US scientists developed the weapon.
• 2003 – US Centres for Disease Control and Prevention (CDC) patented the weapon in its first commercial application (SARS).
• 2005 – mRNA spike protein was declared a biological “belligerent” technology.
• 2016 – Proceedings of the published National Academy of Sciences article ‘SARS-Like W1V1-COV Poised for Human Emergence’. W1V1-COV refers to the first covid-like virus that was produced by the Wuhan Institute of Virology. The article states that the virus is ready for release and describes in detail how it can best be released.

He also exposed more outrageous covid crimes that include collusion, racketeering and criminal conspiracy murder.

Dr. Martin named the chief culprits as Peter Daszak, Ralph Baric, Jeremy Farrar, Chris Elias, Tedros Ghebreyesus, Bill Gates, Anthony Fauci, the World Health Organisation, the Defence Advanced Research Projects Agency (“DARPA”), the United Nations, Rockefeller Foundation, the Wellcome Trust and the Gates Foundation.

To avoid criminal investigation or responsibility, the GAVI Vaccine Alliance’s research projects have been placed under the World Health Organisation (“WHO”) and, according to the WHO Charter, they cannot be investigated or prosecuted for crimes committed.  GAVI, based in Geneva, Switzerland, also enjoys diplomatic immunity and cannot be prosecuted by the local authorities.

You can read a more detailed description of Dr. Martin’s lecture published by TKP HERE.

If you are unable to watch the video above on Rumble, you can watch it on BitChute HERE.

Who is Dr. David Martin?

The following is according to a biography uploaded on the World Intellectual Property Organisation (“WIPO”) website.

Dr. David Martin is the founding CEO of M∙CAM Inc. M∙CAM is the international leader in intellectual property-based financial risk management. From auditing patent quality for governments and patent offices to providing state-of-the-art actuarial risk management systems and solutions to the largest banks and insurance companies, M∙CAM has established a global standard in patent quality and commercial validity assessment and management.

A spokesperson for global intellectual property accountability and quality reform, Dr. Martin has worked closely with the United States Congress, and numerous trade and finance regulatory agencies in the United States, Europe and Asia, in advocating and deploying infrastructure to support growing reliance on proprietary rights in business transactions. M∙CAM has supported the modernisation of intellectual property, tax, and accounting laws through its work with oversight agencies and policymakers.

Dr. Martin has founded several for-profit and non-profit companies and organizations and serves on several boards. He was the founding CEO of Mosaic Technologies Inc., a company that developed and commercialized advanced computational linguistics technologies, dynamic data compression and encryption technologies, electrical field transmission technology, medical diagnostics, and stealth/anechoic technology. He was a founding member of Japan’s Institute for Interface Science & Technology. He founded and served as Executive Director of the Charlottesville Venture Group. He has served as a board member for the Research Institute for Small and Emerging Business (Washington D.C.), the Academy for Augmenting Grassroots Technological Innovations (India), the IST (Japan) the Charlottesville Regional Chamber of Commerce (Virginia), and the Charlottesville Industrial Development Agency (Virginia).

As a former Assistant Professor at the University of Virginia’s School of Medicine, Dr. Martin founded the University’s first wholly-owned, for-profit, research and development and technology transfer corporation. Engaged in domestic and international technology transfer, clinical research, and financing, this company pioneered new techniques of innovation management that have become industry standards. In 1999, Dr. Martin was appointed by the Governor of the Commonwealth of Virginia to serve on the Joint Commission on Technology and Science and has served the General Assembly and Virginia’s Centre for Innovative Technology on numerous occasions.

Dr. Martin’s work with the Batten Institute at the Darden Graduate School of Business Administration at the University of Virginia and his related work at the Indian Institute for Management in Ahmedabad India has brought unprecedented curricular focus to areas of intangible asset risk management, finance, and accounting standards. In addition to his academic work, Dr. Martin has closely advised intellectual property-based finance and investment programs in India, China, Denmark, the European Union, the United Kingdom, South Africa, the Islamic Republic of Iran, the United States, and the United Arab Emirates.

Dr. Martin has publications in law, medicine, engineering, finance and education. He maintains active research in the fields of linguistic genomics and fractal financial risk modelling, as well as continuing his over 15 years of research in cellular membrane ionic signalling.